Difficulty: Medium
Average Score: 95%
Practice
A drug for which research has shown an adverse effect in animals but not in pregnant women would be categorized as Category
Correct answer
C
Rationale
In this question from the ATI Pharmacology book, the correct answer is option C) D. The rationale behind this is related to the FDA's categorization of drugs based on their potential risks during pregnancy. Category D includes drugs where human studies have shown fetal risks, but the potential benefits may outweigh the risks in certain situations.
Option A) A is incorrect because Category A includes drugs that have been shown to be safe in pregnant women based on adequate and well-controlled studies.
Option B) B is incorrect because Category B includes drugs that have not shown fetal risks in animal studies but have not been adequately studied in pregnant women.
Option D) C is incorrect because Category C includes drugs for which animal studies have shown adverse effects on the fetus, but there are no adequate studies in pregnant women.
Educationally, understanding the FDA pregnancy categories is crucial for healthcare professionals to make informed decisions when prescribing medications to pregnant women. It emphasizes the importance of weighing the potential risks and benefits of drug therapy during pregnancy to ensure the best possible outcomes for both the mother and the fetus.
Option A) A is incorrect because Category A includes drugs that have been shown to be safe in pregnant women based on adequate and well-controlled studies.
Option B) B is incorrect because Category B includes drugs that have not shown fetal risks in animal studies but have not been adequately studied in pregnant women.
Option D) C is incorrect because Category C includes drugs for which animal studies have shown adverse effects on the fetus, but there are no adequate studies in pregnant women.
Educationally, understanding the FDA pregnancy categories is crucial for healthcare professionals to make informed decisions when prescribing medications to pregnant women. It emphasizes the importance of weighing the potential risks and benefits of drug therapy during pregnancy to ensure the best possible outcomes for both the mother and the fetus.